Amgen (AMGN) Tops Q1 EPS by 23c; Boosts Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. PTC
4. MSFT
5. SPY
6. META
7. GMAB
8. GOOGL
9. AMD
10. BBIO

Go back to Amgen (AMGN) Tops Q1 EPS by 23c; Boosts Outlook

Amgen Reports First Quarter 2018 Financial Results

April 24, 2018 4:01 PM EDT

THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2018. Key results include:

Total revenues increased 2 percent versus the first quarter of 2017 to $5.6 billion. Product sales grew 3 percent globally. All new and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 16 percent to $3.25 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding. GAAP operating income... More